Business Description
Alembic Pharmaceuticals Ltd
NAICS : 325412
ISIN : INE901L01018
Compare
Compare
Traded in other countries / regions
533573.India IPO Date
2011-09-20Description
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.14 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 1.02 | |||||
| Interest Coverage | 12.51 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 6.63 | |||||
| Beneish M-Score | -2.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.5 | |||||
| 3-Year EBITDA Growth Rate | -15.5 | |||||
| 3-Year EPS without NRI Growth Rate | -19.2 | |||||
| 3-Year FCF Growth Rate | -16.4 | |||||
| 3-Year Book Growth Rate | -1.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 21.56 | |||||
| Future 3-5Y Total Revenue Growth Rate | 11.02 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.31 | |||||
| 9-Day RSI | 55.84 | |||||
| 14-Day RSI | 51 | |||||
| 6-1 Month Momentum % | 12.2 | |||||
| 12-1 Month Momentum % | 47.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.73 | |||||
| Quick Ratio | 0.81 | |||||
| Cash Ratio | 0.07 | |||||
| Days Inventory | 324.33 | |||||
| Days Sales Outstanding | 65.65 | |||||
| Days Payable | 149 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.01 | |||||
| Dividend Payout Ratio | 0.34 | |||||
| Forward Dividend Yield % | 1.01 | |||||
| 5-Year Yield-on-Cost % | 1.01 | |||||
| Shareholder Yield % | 1.1 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.77 | |||||
| Operating Margin % | 11.65 | |||||
| Net Margin % | 10.36 | |||||
| FCF Margin % | 7.62 | |||||
| ROE % | 13.69 | |||||
| ROA % | 9.64 | |||||
| ROIC % | 11.67 | |||||
| ROC (Joel Greenblatt) % | 14.63 | |||||
| ROCE % | 15.58 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.9 | |||||
| Forward PE Ratio | 31.36 | |||||
| PE Ratio without NRI | 33.72 | |||||
| Shiller PE Ratio | 25.47 | |||||
| Price-to-Owner-Earnings | 35.42 | |||||
| PS Ratio | 3.41 | |||||
| PB Ratio | 4.33 | |||||
| Price-to-Tangible-Book | 4.38 | |||||
| Price-to-Free-Cash-Flow | 44.69 | |||||
| Price-to-Operating-Cash-Flow | 26.47 | |||||
| EV-to-EBIT | 29.27 | |||||
| EV-to-EBITDA | 21.45 | |||||
| EV-to-Revenue | 3.57 | |||||
| EV-to-FCF | 44.24 | |||||
| Price-to-Projected-FCF | 3.96 | |||||
| Price-to-Median-PS-Value | 1.06 | |||||
| Price-to-Graham-Number | 2.57 | |||||
| Price-to-Net-Current-Asset-Value | 15.08 | |||||
| Earnings Yield (Greenblatt) % | 3.41 | |||||
| FCF Yield % | 2.21 | |||||
| Forward Rate of Return (Yacktman) % | -4.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alembic Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 62,407.4 | ||
| EPS (TTM) (₹) | 32.88 | ||
| Beta | 0.65 | ||
| Volatility % | 49.62 | ||
| 14-Day RSI | 51 | ||
| 14-Day ATR (₹) | 39.552756 | ||
| 20-Day SMA (₹) | 1073.5575 | ||
| 12-1 Month Momentum % | 47.57 | ||
| 52-Week Range (₹) | 737.45 - 1296.15 | ||
| Shares Outstanding (Mil) | 196.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alembic Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alembic Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alembic Pharmaceuticals Ltd Frequently Asked Questions
What is Alembic Pharmaceuticals Ltd(BOM:533573)'s stock price today?
The current price of BOM:533573 is ₹1089.20. The 52 week high of BOM:533573 is ₹1296.15 and 52 week low is ₹737.45.
When is next earnings date of Alembic Pharmaceuticals Ltd(BOM:533573)?
The next earnings date of Alembic Pharmaceuticals Ltd(BOM:533573) is .
Does Alembic Pharmaceuticals Ltd(BOM:533573) pay dividends? If so, how much?
The Dividend Yield %  of Alembic Pharmaceuticals Ltd(BOM:533573) is 1.01% (As of Today), Highest Dividend Payout Ratio of Alembic Pharmaceuticals Ltd(BOM:533573) was 0.57. The lowest was 0.09. And the median was 0.2. The  Forward Dividend Yield % of Alembic Pharmaceuticals Ltd(BOM:533573) is 1.01%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers